NL-OMON38561已完成不适用
Pharmacokinetic drug interaction study between rAltegraVIr and ATORvastatin (AVIATOR). - AVIATOR
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subject is at least 18 and not older than 55 years at screening.
- •2. Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to the first dosing
- •3. Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.
- •4. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- •5. Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to the first dose. Results of biochemistry, haematology and urinalysis testing should be within the laboratory's reference ranges. If laboratory results are not within the reference ranges, the subject is included on condition that the Investigator judges that the deviations are not clinically relevant. This should be clearly recorded.
- •6. Subject has a normal blood pressure and pulse rate, according to the Investigator's judgement.
排除标准
- •1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
- •2. Positive HIV test.
- •3. Positive hepatitis B or C test.
- •4. Pregnant female (as confirmed by an hCG test performed less than 4 weeks before day 1) or breast-feeding female. Female subjects of childbearing potential without adequate contraception, e.g. hysterec-tomy, bilateral tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier methods, or two years post-menopausal. They must agree to take precautions in order to prevent a pregnancy throughout the entire conduct of the study.
- •5. Therapy with any drug (for two weeks preceding dosing), except for acetaminophen.
- •6. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), psychiatric disorders, gastro-intestinal disor-ders, renal and hepatic disorders, hormonal disorders (especially dia-betes mellitus), coagulation disorders, musculoskeletal and con-nective tissue disorders.
- •7. Relevant history or current condition that might interfere with drug ab-sorption, distribution, metabolism or excretion.
- •8. History of or current abuse of drugs, alcohol or solvents.
- •9. Inability to understand the nature and extent of the study and the pro-cedures required.
- •10. Participation in a drug study within 60 days prior to the first dose.
- •11. Donation of blood within 60 days prior to the first dose.
- •12. Febrile illness within 3 days before the first dose.
研究者
相似试验
已完成
不适用
Evaluation of Pharmacokinetic interaction between vitamin K1 and ezetimibeHealthy volunteerJPRN-UMIN000002327Department of Hospital Pharmacy, Hamamatsu University School of Medicine10
已完成
1 期
Evaluation of pharmacokinetic interactions between the antidiabetic metformin andthe antibiotic trimethoprim.E11.90DRKS00000481niversität Heidelberg, Medizinische Fakultät24
已完成
不适用
The pharmacokinetic study of drug interaction between metformin and pyrimethamine from microdose to clinical dose in adult healthy volunteershealthy male subjectsJPRN-UMIN000002739Clinical trial Center,Kitasato University East Hospital8
已完成
1 期
Pharmacokinetic drug-drug interaction study between oral 300 mg netupitant/0.50 mg palonosetron fixed dose combination (Akynzeo®) and oral dexamethasone to evaluate the duration of the CYP3A4 inhibition in healthy subjectsInhibitory effect on CYP3A4ISRCTN93845260Helsinn Healthcare SA24
进行中（未招募）
不适用
Study on the pharmacodynamic interactions between propofol and sevoflurane during induction of anesthesia.AnesthesiaEUCTR2005-004632-40-BEniversity Hospital Ghent60